T. Rowe Price Associates
NVCT icon

T. Rowe Price Associates’s Nuvectis Pharma NVCT Stock Holding History

T. Rowe Price Associates’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$94K Buy
+12,048
New +$103K ﹤0.01% 3012

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates's NVCT Position: Q1 2026 in Review

T. Rowe Price Associates opened a new position in Nuvectis Pharma (NVCT) in Q1 2026: 12,048 shares worth $94K. The stake represents ﹤0.01% of the portfolio and ranks #3012 among its holdings.

62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • T. Rowe Price Associates held 12,048 shares of Nuvectis Pharma worth $94K as of Q1 2026.
  • Nuvectis Pharma was a new T. Rowe Price Associates position in Q1 2026.
  • Nuvectis Pharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #3012 holding.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.